Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Branaplam Pediatric vs Adult Formulations and Food Effect
NCT05330286Phase 1Terminated
- Sponsor
- Novartis
- Start
- Apr 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of branaplam in Huntington's disease (HD) (4 arms), sponsored by Novartis. Primary endpoints: Plasma Maximum Concentration at Day 15, Area Under the Plasma Concentration-Time Curve to Last Measurable Concentration at Day 15 and 1 more. Started Apr 2022; status: terminated.
02
Drugs
branaplam
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT05330286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330286.